modelSaxagliptinAndDapagliflo
Extends from Pharmacolibrary.Drugs.ATC.A.A10BD21.
Information
| name: | SaxagliptinAndDapagliflozin | |
| ATC code: | A10BD21 | route: | oral |
| compartments: | 1 | |
| dosage: | 5 | mg |
| volume of distribution: | 57 | L |
| clearance: | 12.6 | L/h (saxagliptin), 9.2 L/h (dapagliflozin) |
| other parameters in model implementation | ||
Saxagliptin and dapagliflozin is a fixed-dose combination drug used to treat type 2 diabetes mellitus in adults. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor and dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. This combination helps to improve glycemic control by targeting different mechanisms. The drug is approved for clinical use.
Pharmacokinetics
No population pharmacokinetic models or detailed PK parameters published in the literature for the fixed-dose combination. Individual PK parameters for saxagliptin and dapagliflozin are available but no combined PK study found. Estimates below are based on typical adult values for each component after oral administration.
References
Boulton, DW, et al., & Lacreta, F (2013). Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. British journal of clinical pharmacology 75(3) 763–768. DOI:10.1111/j.1365-2125.2012.04391.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/22823746
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)